WCN26-2145 IMPACT OF HISTOLOGY ON EFFICACY OF SPARSENTAN THERAPY IN IGA NEPHROPATHY: CENTRAL BIOPSY REVIEW OF PATIENTS IN THE PROTECT TRIAL

Conclusion:This case highlights the therapeutic potential of telitacicept in overlapping autoimmune conditions.By targeting BAFF and APRIL pathways, telitacicept may provide dual benefits in controlling renal autoimmunity and antibody-mediated neuromuscular dysfunction.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.